Skip to main content

Capstone Holding Corp.

For the period ended Sep 30, 2025. Filed Nov 18, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 18, 2025

CAPS$2.10+10.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. EXHIBITS

Exhibit
NumberExhibit Description
2.1Membership Interest Purchase Agreement, by and between Capstone Holding Corp., D22L, Inc., David Clary, and Stuart Powell (incorporated by reference to exhibit 2.1 to current report on Form 8-K filed with the SEC on August 18, 2025)
3.1Certificate of Designation of Preferences, Rights and Limitations of Series Z 8% Non-Convertible Preferred Stock (incorporated by reference to exhibit 3.1 to current report on Form 8-K filed with the SEC on October 6, 2025)
10.1Form of Securities Purchase Agreement, by and between Capstone Holding Corp. and the Buyer (incorporated by reference to exhibit 10.1 to current report on Form 8-K filed with the SEC on August 4, 2025)
10.2Form of Senior Secured Convertible Note (incorporated by reference to exhibit 10.2 to current report on Form 8-K filed with the SEC on August 4, 2025)
10.3Form of Registration Rights Agreement, by and between Capstone Holding Corp. and the Buyer (incorporated by reference to exhibit 10.3 to current report on Form 8-K filed with the SEC on August 4, 2025)
10.4Form of Security Agreement, by and between Capstone Holding Corp. and the Buyer (incorporated by reference to exhibit 10.4 to current report on Form 8-K filed with the SEC on August 4, 2025)
10.5Conversion Price Voluntary Adjustment Notice (incorporated by reference to exhibit 10.1 to current report on Form 8-K filed with the SEC on August 15, 2025)
10.6Exchange Agreement by and among Capstone Holding Corp., BP Peptides, LLC, and Brookstone Partners Acquisition XXI Corporation, dated September 30, 2025 (incorporated by reference to exhibit 10.1 to current report on Form 8-K filed with the SEC on October 6, 2025)
10.7Conversion Price Voluntary Adjustment Notice, dated October 5, 2025 (incorporated by reference to exhibit 10.2 to current report on Form 8-K filed with the SEC on October 6, 2025)
31.1*Certification pursuant to 18 U.S.C. Section 1350 Section 302 of the Sarbanes-Oxley Act of 2002 - Chief Executive Officer
31.2*Certification pursuant to 18 U.S.C. Section 1350 Section 302 of the Sarbanes-Oxley Act of 2002 - Chief Financial Officer
32.1**Certification pursuant to 18 U.S.C. Section 1350 Section 906 of the Sarbanes-Oxley Act of 2002 - Chief Executive Officer
32.2**Certification pursuant to 18 U.S.C. Section 1350 Section 906 of the Sarbanes-Oxley Act of 2002 - Chief Financial Officer
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*Cover Page Interactive Data File (embedded within the Inline XBRL document)
*Filed herewith.
**Furnished herewith
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.